Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

US launch of new microbiome products generates plenty of interest, says Optibiotix

The event was attended by 16,500 ingredient buyers and suppliers from the supplement, beverage, functional food, personal care and sports nutrition industries
picture of gut
Microbiome is attracting huge interest from food and pharma groups

OptiBiotix Health PLC (LON:OPTI) has launched its SlimBiome and LP products in the US at the Supply Side West trade show.

Both products recently received FDA registration and the presentation at Supply Side West was the first in a number of steps to attract food, beverage, consumer healthcare and pharmaceutical partners for distribution and sale into the US market.

READ: Optibiotix Health lines up the targets for its “Precision microbiome engineering”

Cholesterol reducer LP was co-exhibited with Sacco, one of the largest suppliers of probiotic ingredients, while appetite suppressant SlimBiome was co-exhibited with specialty ingredients manufacturer, Cereal Ingredients. 

The event was attended by 16,500 ingredient buyers and suppliers from the supplement, beverage, functional food, personal care and sports nutrition industries with high interest from around the world, said the company.

Additionally, Optibiotix said that Sacco has appointed Dr Lucio Lepera as product manager for LP’s entry into the US probiotic market and extend it into the dairy market.

READ: OptiBiotix 'gaining real commercial traction' - CEO Stephen O'Hara

Cereal Ingredients, meanwhile, has incorporated SlimBiome into its range of cereal-based particulates and speciality ingredients that includes bakery products, breakfast cereals, crackers, toppings, products that extend it into the nutraceutical, health and wellbeing industry sectors. 

Stephen O'Hara, OptiBiotix’s chief executive, said in a statement: "We are extremely pleased with the very high level of interest from both national and multinational companies interested in our products and the opportunity to meet with senior US and Asian decision makers at Supply Side West. 

He added looking for partners was a low risk, low cost approach to accessing multiple consumer healthcare and pharmaceutical markets around the world with multiple products.

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

Workers at CERN
September 29 2017
The technology being developed is cheaper and smaller than the current units, which are almost prohibitively expensive
diagram of the human microbiome
September 13 2017
OptiBiotix is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin
1504120610_biotechLatest.jpg
August 31 2017
The company is poised for a milestone-rich period over the next year or so

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use